Immunogenic Cell Death Amplified by Co-localized Adjuvant Delivery for Cancer Immunotherapy
Year: 2017
Type: article
Abstract: Despite their potential, conventional whole-cell cancer vaccines prepared by freeze–thawing or irradiation have shown limited therapeutic efficacy in clinical trials. Recent studies have indicated that cancer cells treated with certain chemotherapeutics, such as mitoxantrone, can undergo immunogenic cell death (ICD) and initiate antitumor immune responses. However, it remains unclear how to exploit ICD for cancer immunotherapy. Here, we present a new material-based strategy for converting immunogenically dying tumor cells into a powerful platform for cancer vaccination and demonstrate their therapeutic potential in murine models of melanoma and colon carcinoma. We have generated immunogenically dying tumor cells surface-modified with adjuvant-loaded nanoparticles. Dying tumor cells laden with adjuvant nanodepots efficiently promote activation and antigen cross-presentation by dendritic cells in vitro and elicit robust antigen-specific CD8α + T-cells in vivo. Furthermore, whole tumor-cell vaccination combined with immune checkpoint blockade leads to complete tumor regression in ∼78% of CT26 tumor-bearing mice and establishes long-term immunity against tumor recurrence. Our strategy presented here may open new doors to “personalized” cancer immunotherapy tailored to individual patient’s tumor cells.
Source: Nano Letters
Language: English
Subfield: Immunology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: green
Funders: Michigan Economic Development Corporation, Melanoma Research Alliance, University of Michigan, Alberta Emerald Foundation, National Heart, Lung, and Blood Institute, National Cancer Institute, National Institute of Allergy and Infectious Diseases, National Institute of Biomedical Imaging and Bioengineering, Division of Chemical, Bioengineering, Environmental, and Transport Systems, Congressionally Directed Medical Research Programs
Awards: G3003801229, Novel approaches for immunotherapy against melanoma, Elicitation of mucosal immune responses against HIV, G3488383117, B Cell Exosome and Nanoparticle Treatment of Allergic Asthma, Secreted SOCS Proteins as Vectors of Lung Macrophage to Epithelial Cell Crosstalk, Tuning Biomaterials-immune cell interactions for treatment of glioblastoma multiforme, A New Vaccination Strategy for Treatment of Melanoma, Environmental Regulation of Cancer Stem Cell Plasticity in Metastasis, Engineering Nanomaterials to Prime Immunity
OpenAlex ID: W2768677065
